• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

根据 2 家荷兰学术医疗中心的指南,对植入式除颤器进行一级预防后的医疗保健利用情况。

Health care utilisation after defibrillator implantation for primary prevention according to the guidelines in 2 Dutch academic medical centres.

机构信息

Department of Cardiology, Erasmus MC, Rotterdam, PO Box 2040, 3000, CA, the Netherlands.

出版信息

Neth Heart J. 2011 Oct;19(10):405-11. doi: 10.1007/s12471-011-0176-3.

DOI:10.1007/s12471-011-0176-3
PMID:21773744
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3189312/
Abstract

BACKGROUND

The benefit of implantable defibrillators (ICDs) for primary prevention remains debated. We analysed the implications of prophylactic ICD implantation according to the guidelines in 2 tertiary hospitals, and made a healthcare utilisation inventory.

METHODS

The cohort consisted of all consecutive patients with coronary artery disease (CAD) or dilated cardiomyopathy (DCM) receiving a primary prophylactic ICD in a contemporary setting (2004-2008). Follow-up was obtained from hospital databases, and mortality checked at the civil registry. Additional data came from questionnaires sent to general practitioners.

RESULTS

There were no demographic differences between the 2 centres; one had proportionally more CAD patients and more resynchronisation therapy (CRT-D). The 587 patients were followed over a median of 28 months, and 50 (8.5%) patients died. Appropriate ICD intervention occurred in 123 patients (21%). There was a small difference in intervention-free survival between the 2 centres. The questionnaires revealed 338 hospital admissions in 52% of the responders. Device-related admissions happened on 68 occasions, in 49/276 responders. The most frequently reported ICD-related admission was due to shocks (20/49 patients); for other cardiac problems it was mainly heart failure (52/99). Additional outpatient visits occurred in 19%.

CONCLUSION

Over a median follow-up of 2 years, one fifth of prophylactic ICD patients receive appropriate interventions. A substantial group undergoes readmission and additional visits. The high number of admissions points to a very ill population. Overall mortality was 8.5%. The 2 centres employed a similar procedure with respect to patient selection. One centre used more CRT-D, and observed more appropriate ICD interventions.

摘要

背景

植入式心脏除颤器(ICD)在一级预防中的获益仍存在争议。我们分析了根据 2 家三级医院的指南进行预防性 ICD 植入的影响,并制作了一份医疗资源利用清单。

方法

该队列由在当代环境下(2004-2008 年)接受一级预防性 ICD 的所有连续冠状动脉疾病(CAD)或扩张型心肌病(DCM)患者组成。通过医院数据库获得随访信息,并在公民登记处检查死亡率。额外的数据来自发送给全科医生的调查问卷。

结果

2 家中心之间没有人口统计学差异;一家中心的 CAD 患者比例更高,且接受心脏再同步治疗(CRT-D)的患者更多。587 例患者的中位随访时间为 28 个月,有 50 例(8.5%)患者死亡。123 例(21%)患者发生了适当的 ICD 干预。2 家中心的无干预生存存在微小差异。调查问卷显示,52%的应答者中有 338 例住院。设备相关的住院共发生 68 次,在 49/276 名应答者中。报告最频繁的 ICD 相关住院原因是电击(49 例患者中的 20 例);对于其他心脏问题,主要是心力衰竭(99 例患者中的 52 例)。另外还发生了 19%的门诊就诊。

结论

在中位随访 2 年期间,五分之一的预防性 ICD 患者接受了适当的干预。相当一部分患者需要再次住院和额外就诊。高比例的住院人数表明患者病情严重。总死亡率为 8.5%。2 家中心在患者选择方面采用了类似的程序。一家中心使用了更多的 CRT-D,并观察到更多适当的 ICD 干预。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3805/3189312/f9658beca0c2/12471_2011_176_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3805/3189312/0be719d9ab27/12471_2011_176_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3805/3189312/b9ff08ca71a0/12471_2011_176_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3805/3189312/44e985f87263/12471_2011_176_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3805/3189312/f9658beca0c2/12471_2011_176_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3805/3189312/0be719d9ab27/12471_2011_176_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3805/3189312/b9ff08ca71a0/12471_2011_176_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3805/3189312/44e985f87263/12471_2011_176_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3805/3189312/f9658beca0c2/12471_2011_176_Fig4_HTML.jpg

相似文献

1
Health care utilisation after defibrillator implantation for primary prevention according to the guidelines in 2 Dutch academic medical centres.根据 2 家荷兰学术医疗中心的指南,对植入式除颤器进行一级预防后的医疗保健利用情况。
Neth Heart J. 2011 Oct;19(10):405-11. doi: 10.1007/s12471-011-0176-3.
2
3
Long-term follow-up of prophylactic implantable cardioverter-defibrillator-only therapy: comparison of ischemic and nonischemic heart disease.植入式心律转复除颤器预防治疗的长期随访:缺血性与非缺血性心脏病的比较。
Clin Cardiol. 2011 Dec;34(12):761-7. doi: 10.1002/clc.20970. Epub 2011 Oct 28.
4
Factors predisposing to ventricular tachyarrhythmia leading to appropriate ICD intervention in patients with coronary artery disease or non-ischaemic dilated cardiomyopathy.导致冠心病或非缺血性扩张型心肌病患者 ICD 干预的致室性心律失常的相关因素。
Kardiol Pol. 2012;70(12):1264-75.
5
Follow-up of implantable cardioverter-defibrillator therapy: comparison of coronary artery disease and dilated cardiomyopathy.植入式心脏复律除颤器治疗的随访:冠状动脉疾病与扩张型心肌病的比较。
Neth Heart J. 2014 Oct;22(10):431-7. doi: 10.1007/s12471-014-0595-z.
6
Appropriate ICD therapy in patients with idiopathic dilated cardiomyopathy: long term follow-up.特发性扩张型心肌病患者的适当植入式心律转复除颤器治疗:长期随访
Int Heart J. 2006 Sep;47(5):763-73. doi: 10.1536/ihj.47.763.
7
Factors influencing the use of subcutaneous or transvenous implantable cardioverter-defibrillators: results of the European Heart Rhythm Association prospective survey.影响皮下或经静脉植入式心脏复律除颤器使用的因素:欧洲心律协会前瞻性调查结果。
Europace. 2018 May 1;20(5):887-892. doi: 10.1093/europace/euy009.
8
[Arrhythmia, device interventions and mortality analysis in patients with implanted cardioverter-defibrillator with/without resynchronisation therapy in dilative cardiomyopathy in primary prevention of sudden cardiac death].[扩张型心肌病患者植入式心脏复律除颤器在心脏性猝死一级预防中有无再同步治疗的心律失常、器械干预及死亡率分析]
Pol Merkur Lekarski. 2016 Apr;40(238):216-22.
9
Contemporary use of devices in chronic heart failure in the Netherlands.荷兰慢性心力衰竭患者中装置的当代应用。
ESC Heart Fail. 2020 Aug;7(4):1771-1780. doi: 10.1002/ehf2.12740. Epub 2020 May 12.
10
Appropriate implantable cardioverter-defibrillator interventions in cardiac resynchronization therapy-defibrillator (CRT-D) patients undergoing device replacement: time to downgrade from CRT-D to CRT-pacemaker? Insights from real-world clinical practice in the DECODE CRT-D analysis.心脏再同步治疗除颤器(CRT-D)患者更换器械时的适当植入式心律转复除颤器干预:是否需要从 CRT-D 降级为 CRT-起搏器?DECODE CRT-D 分析中的真实临床实践见解。
Europace. 2018 Sep 1;20(9):1475-1483. doi: 10.1093/europace/eux323.

引用本文的文献

1
Optimisation of cardiac resynchronization therapy in clinical practice during exercise.优化临床实践中心脏再同步治疗在运动中的效果。
Neth Heart J. 2013 Oct;21(10):458-63. doi: 10.1007/s12471-013-0438-3.
2
Implementation of guidelines for implantable cardioverter-defibrillator therapy in clinical practice: Which patients do benefit?在临床实践中实施植入式心脏复律除颤器治疗指南:哪些患者受益?
Neth Heart J. 2013 Jun;21(6):274-83. doi: 10.1007/s12471-013-0407-x.
3
Phantom shocks: innocent bystander or complication of implantable cardioverter defibrillator therapy?

本文引用的文献

1
Effectiveness of prophylactic implantation of cardioverter-defibrillators without cardiac resynchronization therapy in patients with ischaemic or non-ischaemic heart disease: a systematic review and meta-analysis.预防性植入心脏除颤器而不进行心脏再同步治疗在缺血性或非缺血性心脏病患者中的效果:系统评价和荟萃分析。
Europace. 2010 Nov;12(11):1564-70. doi: 10.1093/europace/euq329.
2
The prognosis of implantable defibrillator patients treated with cardiac resynchronization therapy: comorbidity burden as predictor of mortality.心脏再同步治疗的植入式除颤器患者的预后:合并症负担是死亡率的预测指标。
Europace. 2011 Jan;13(1):62-9. doi: 10.1093/europace/euq328. Epub 2010 Sep 10.
3
假性电击:无辜旁观者还是植入式心脏复律除颤器治疗的并发症?
Neth Heart J. 2013 Apr;21(4):189-90. doi: 10.1007/s12471-013-0388-9.
European utilization of the implantable defibrillator: has 10 years changed the 'enigma'?
欧洲植入式除颤器的应用:10 年是否改变了“谜团”?
Europace. 2010 Aug;12(8):1063-9. doi: 10.1093/europace/euq282.
4
Pitfalls in health-economic evaluations: the case of cost-effectiveness of prophylactic implantable cardioverter-defibrillator therapy in Belgium.
Europace. 2009 Dec;11(12):1571-3. doi: 10.1093/europace/eup290. Epub 2009 Oct 8.
5
Defibrillator implantation early after myocardial infarction.心肌梗死后早期植入除颤器。
N Engl J Med. 2009 Oct 8;361(15):1427-36. doi: 10.1056/NEJMoa0901889.
6
Association of physician certification and outcomes among patients receiving an implantable cardioverter-defibrillator.植入式心脏复律除颤器患者的医生认证与治疗结果的关联
JAMA. 2009 Apr 22;301(16):1661-70. doi: 10.1001/jama.2009.547.
7
Lifetime cost-effectiveness of prophylactic implantation of a cardioverter defibrillator in patients with reduced left ventricular systolic function: results of Markov modelling in a European population.左心室收缩功能降低患者预防性植入心脏复律除颤器的终身成本效益:欧洲人群马尔可夫模型的结果
Europace. 2009 Jun;11(6):716-26. doi: 10.1093/europace/eup068. Epub 2009 Apr 9.
8
Primary prevention with ICDs, are we on the right track?植入式心脏复律除颤器的一级预防,我们是否走在正确的道路上?
Neth Heart J. 2009 Mar;17(3):92-4. doi: 10.1007/BF03086225.
9
Predictors of long-term mortality in Multicenter Automatic Defibrillator Implantation Trial II (MADIT II) patients with implantable cardioverter-defibrillators.多中心自动除颤器植入试验II(MADIT II)中植入式心脏复律除颤器患者长期死亡率的预测因素
Heart Rhythm. 2009 Apr;6(4):468-73. doi: 10.1016/j.hrthm.2008.12.023. Epub 2008 Dec 24.
10
Increasing hazard of Sprint Fidelis implantable cardioverter-defibrillator lead failure.美敦力 Sprint Fidelis植入式心脏复律除颤器导线故障风险增加。
Heart Rhythm. 2009 May;6(5):605-10. doi: 10.1016/j.hrthm.2009.02.024. Epub 2009 Feb 20.